INSP · XBRL financial data

Inspire Medical Systems financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (INSP's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	115,381	233,394	407,856	624,799	802,804	911,981
Cost of goods and services sold	17,623	33,279	66,115	96,576	122,986	133,225
Gross profit	97,758	200,115	341,741	528,223	679,818	778,756
Research and development	26,092	37,350	68,645	116,536	114,128	103,165
Selling, general and administrative	127,874	202,615	320,688	451,958	529,607	624,637
Total operating expenses	153,966	239,965	389,333	568,494	—	—
Operating income (loss)	(56,208)	(39,850)	(47,592)	(40,271)	36,083	50,954
Interest income	1,092	125	—	—	—	—
Interest expense	2,117	2,128	1,677	0	22	137
Other income (expense)	145	(117)	(49)	(195)	(855)	(2,656)
Income tax expense (benefit)	115	72	613	1,247	4,944	(79,725)
Net income (loss)	(57,203)	(42,042)	(44,881)	(21,153)	53,509	145,422
Earnings per share, basic USD per share	(2.19)	(1.54)	(1.60)	(0.72)	1.80	4.95
Earnings per share, diluted USD per share	(2.19)	(1.54)	(1.60)	(0.72)	1.75	4.89
Weighted average shares, basic thousands of shares	26,073	27,263	28,072	29,302	29,763	29,369
Weighted average shares, diluted thousands of shares	26,073	27,263	28,072	29,302	30,543	29,757

Fiscal years (INSP's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	190,518	214,467	441,592	185,537	150,150	104,813
Short-term investments	43,844	0	9,821	274,838	295,396	203,455
Marketable securities	—	—	9,821	274,838	295,396	203,455
Marketable securities, non-current	0	0	0	9,143	70,995	96,330
Accounts receivable	25,063	34,179	61,228	89,884	93,068	119,692
Inventory	8,479	17,231	11,886	33,885	80,118	145,293
Total current assets	269,869	268,537	530,032	593,739	630,806	583,652
Property and equipment, net	5,311	8,486	17,249	39,984	71,925	97,872
Right-of-use asset	5,805	7,919	6,880	22,667	23,314	23,532
Total assets	281,189	295,084	564,876	676,811	808,383	907,317
Accrued liabilities	13,516	20,454	34,339	39,266	49,814	59,490
Total current liabilities	20,725	41,307	61,186	78,105	88,501	96,055
Lease liability, non-current	5,886	8,796	7,536	24,846	30,039	29,998
Total liabilities	51,442	66,036	68,868	104,297	118,688	126,157
Accumulated deficit	(237,347)	(279,389)	(324,270)	(345,423)	(291,914)	(146,492)
Total stockholders' equity	229,747	229,048	496,008	572,514	689,695	781,160
Total liabilities and equity	281,189	295,084	564,876	676,811	808,383	907,317
Common shares outstanding (cover page) thousands of shares	27,129	27,529	29,048	29,585	29,669	28,589

Fiscal years (INSP's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(57,203)	(42,042)	(44,881)	(21,153)	53,509	145,422
Stock-based compensation	12,817	26,178	51,970	82,470	116,007	130,259
Depreciation and amortization	840	1,218	1,858	2,846	6,550	13,957
Net cash from operating activities	(53,045)	(20,119)	11,569	24,653	130,246	116,976
Purchases of property and equipment	2,455	4,668	9,096	23,629	39,123	38,499
Net cash from investing activities	86,627	29,139	(19,596)	(294,822)	(113,122)	21,446
Proceeds from issuing common stock	124,654	0	243,801	0	0	—
Share repurchases	—	—	0	0	75,000	175,019
Repayments of long-term debt	0	0	24,500	0	0	—
Net cash from financing activities	134,065	14,948	235,077	13,950	(52,393)	(183,449)
Net change in cash	167,658	23,949	227,125	(256,055)	(35,387)	(45,337)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Inspire Medical Systems	190,803	206,695	46,426*	29.0M	—	Q3 FY26 10-QSep 30, 2026
Masimo	124,600	403,600	45,300	52.4M	—	Q1 FY26 10-QApr 4, 2026
Integer Holdings	14,135	449,661	36,631*	34.0M	—	Q3 FY26 10-QOct 2, 2026
TransMedics Group	491,113	189,948	17,309*	34.7M	—	Q2 FY26 10-QJun 30, 2026
Icu Medical	298,299	551,683	80,150*	25.0M	—	Q2 FY26 10-QJun 30, 2026
PROCEPT BioRobotics	227,914	94,498	(19,251)*	57.3M	11.8 quarters	Q2 FY26 10-QJun 30, 2026
Dentsply Sirona	239,000	898,000	99,000*	199.4M	—	Q2 FY26 10-QJun 30, 2026
iRhythm Holdings	246,679	224,172	51,080*	33.0M	—	Q2 FY26 10-QJun 30, 2026
Merit Medical Systems	503,551	416,244	65,273*	59.9M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.